| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/26/2001 | WO2001029058A1 Rna interference pathway genes as tools for targeted genetic interference |
| 04/26/2001 | WO2001029056A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 04/26/2001 | WO2001029049A2 Imidazole derivatives as phosphodiesterase vii inhibitors |
| 04/26/2001 | WO2001029044A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 04/26/2001 | WO2001029042A1 Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 04/26/2001 | WO2001029041A1 Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase |
| 04/26/2001 | WO2001029039A1 Synthesis and methods of use of 9-substituted guanine derivatives |
| 04/26/2001 | WO2001029038A1 Tricyclic fused-imidazole derivatives |
| 04/26/2001 | WO2001029037A2 Condensed naphthyridines as hiv reverse transcriptase inhibitors |
| 04/26/2001 | WO2001029036A2 Allosteric sites on muscarinic receptors |
| 04/26/2001 | WO2001029030A1 N-substituted 1-(lactone) isoquinolones for treating nervous disorders |
| 04/26/2001 | WO2001029029A1 Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists |
| 04/26/2001 | WO2001029028A1 9- (piperazinylalkyl) carbazoles as bax-modulators |
| 04/26/2001 | WO2001029027A1 2-alkoxybenzene derivatives |
| 04/26/2001 | WO2001029026A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 04/26/2001 | WO2001029025A2 Tyrosine kinase inhibitors |
| 04/26/2001 | WO2001029023A1 Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them |
| 04/26/2001 | WO2001029022A1 Benzopyran derivatives |
| 04/26/2001 | WO2001029015A2 Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists |
| 04/26/2001 | WO2001029013A1 Process for preparing oxazolines from tetrahydrofurans |
| 04/26/2001 | WO2001029012A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029011A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 04/26/2001 | WO2001029009A1 4,5-disubstituted-2-aminopyrimidines |
| 04/26/2001 | WO2001029007A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 04/26/2001 | WO2001029000A2 Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| 04/26/2001 | WO2001028996A2 Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases |
| 04/26/2001 | WO2001028993A2 Tyrosine kinase inhibitors |
| 04/26/2001 | WO2001028991A1 N-cycloalkyl thiooxamide derivatives |
| 04/26/2001 | WO2001028987A1 Benzylcycloalkyl amines as modulators of chemokine receptor activity |
| 04/26/2001 | WO2001028978A1 Bicyclic amino acids as pharmaceutical agents |
| 04/26/2001 | WO2001028592A1 Cobalamin conjugates useful as imaging agents and as antitumor agents |
| 04/26/2001 | WO2001028587A2 Magnetic targeted carrier |
| 04/26/2001 | WO2001028579A2 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 04/26/2001 | WO2001028577A2 Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain |
| 04/26/2001 | WO2001028574A2 Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain |
| 04/26/2001 | WO2001028557A1 Cannabimimetic indole derivatives |
| 04/26/2001 | WO2001028551A1 Agents for promoting fattening of animals and method of promoting fattening |
| 04/26/2001 | WO2001028545A2 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 04/26/2001 | WO2001028543A1 TREATMENT OF EOSINOPHIL ASSOCIATED PATHOLOGIES BY MODULATING PKC-δ ACTIVITY |
| 04/26/2001 | WO2001028537A2 Bissulfonamide derivatives as enzyme inhibitors |
| 04/26/2001 | WO2001028523A1 Powder pharmaceutical formulations |
| 04/26/2001 | WO2001028515A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 04/26/2001 | WO2001028498A2 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 04/26/2001 | WO2001028497A2 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 04/26/2001 | WO2001028494A2 Nordihydroguaiaretic derivatives for use in treatment of tumors |
| 04/26/2001 | WO2001028363A1 Method for treatment of chronic venous insufficiencies using an extract of red vine leaves |
| 04/26/2001 | WO2001005970A3 Gtp-binding protein associated factors |
| 04/26/2001 | WO2000077040A3 Human intracellular signaling molecules |
| 04/26/2001 | WO2000075121A3 Process for preparing 10,11-methanobenzosuberane derivatives |
| 04/26/2001 | WO2000071723A3 Methods for regulating protein conformation using molecular chaperones |
| 04/26/2001 | WO2000070021A3 Differentiated human embryoid cells and a method for producing them |
| 04/26/2001 | WO2000061609B1 Prodrugs of thrombin inhibitors |
| 04/26/2001 | WO2000056889A3 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 04/26/2001 | WO2000055139A3 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 04/26/2001 | WO2000055125A3 N-cyanomethyl amides as protease inhibitors |
| 04/26/2001 | WO2000003244A3 Immortalized human keratinocyte cell line |
| 04/26/2001 | US20010000521 Biological activity inhibiting topoisomerase I and/or topoisomerase II; antitumor agents, viricides |
| 04/26/2001 | US20010000513 Treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation |
| 04/26/2001 | DE19950647A1 Benzopyranoimidazolone and benzothiopyranoimidazolone derivatives as phosphodiesterase-VII inhibitors useful for treatment of e.g. asthma, psoriasis, osteoporosis, cachexia, sepsis, tumors and AIDS |
| 04/26/2001 | CA2389317A1 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 04/26/2001 | CA2388859A1 Inhibitors of neuraminidases |
| 04/26/2001 | CA2388503A1 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 04/26/2001 | CA2388450A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 04/26/2001 | CA2388421A1 Human cub-domain-containing protein and gene encoding the same |
| 04/26/2001 | CA2387972A1 N-substituted 1-(lactone) isoquinolones for treating nervous disorders |
| 04/26/2001 | CA2387925A1 Magnetic targeted carrier composed of iron and porous materials for the targeted delivery of biologically active agents |
| 04/26/2001 | CA2387896A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors |
| 04/26/2001 | CA2387892A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 04/26/2001 | CA2387846A1 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 04/26/2001 | CA2387840A1 Tyrosine kinase inhibitors |
| 04/26/2001 | CA2387786A1 Treatment of eosinophil associated pathologies by modulating pkc-.delta. activity |
| 04/26/2001 | CA2387757A1 Cobalamin conjugates useful as imaging agents and as antitumor agents |
| 04/26/2001 | CA2387748A1 Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain |
| 04/26/2001 | CA2387593A1 Enzyme inhibitors |
| 04/26/2001 | CA2387392A1 Polypeptide fragments comprising c-terminal portion of helicobacter catalase |
| 04/26/2001 | CA2387185A1 Self-cleaving rna sequences and their use for the control of protein synthesis |
| 04/26/2001 | CA2387138A1 Cannabimimetic indole derivatives |
| 04/26/2001 | CA2387041A1 Human sit4 associated proteins like (sapl) proteins and encoding genes; uses thereof |
| 04/26/2001 | CA2387034A1 4,5-disubstituted-2-aminopyrimidines |
| 04/26/2001 | CA2386942A1 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 04/26/2001 | CA2386922A1 Novel polypeptides and polynucleotides encoding same |
| 04/26/2001 | CA2386422A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 04/26/2001 | CA2386401A1 Preparation of cellular components that are substantially free of chromosomal dna |
| 04/26/2001 | CA2386270A1 Rna interference pathway genes as tools for targeted genetic interference |
| 04/26/2001 | CA2386149A1 Allosteric sites on muscarinic receptors |
| 04/26/2001 | CA2386049A1 Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| 04/26/2001 | CA2385958A1 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 04/26/2001 | CA2385472A1 Isoxazolecarboxamide derivatives |
| 04/26/2001 | CA2384789A1 Synthesis and methods of use of 9-substituted guanine derivatives |
| 04/26/2001 | CA2384573A1 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 04/26/2001 | CA2384264A1 Protein tyrosine kinase receptor polynucleotides, polypeptides, and antibodies |
| 04/26/2001 | CA2384240A1 Benzylcycloalkyl amines as modulators of chemokine receptor activity |
| 04/26/2001 | CA2382978A1 Powder pharmaceutical formulations |
| 04/25/2001 | EP1094317A1 Method to identify compounds which modulate FRA-1 expression |
| 04/25/2001 | EP1094109A2 Human G protein-coupled receptor, PFI-010 |
| 04/25/2001 | EP1094076A1 Human G-protein coupled receptor |
| 04/25/2001 | EP1094073A2 Analogs of PTH and PTHRP, their synthesis and use for the treatment of osteoporosis |
| 04/25/2001 | EP1094066A2 Condensed heterocyclic glutamic acid derivatives as antiproliferative agents |
| 04/25/2001 | EP1094064A1 5-arylindolederivatives and their use as serotonin(5-ht1)agonists |
| 04/25/2001 | EP1094063A1 9-(Piperazinylalkyl)carbazoles as Bax-modulators |